Hyperion DeFi, Inc.

Hyperion DeFi, Inc.

HYPD
Hyperion DeFi, Inc.US flagNASDAQ Global Market
3.61
USD
-0.09
- -
18.02MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
7.6
42.55
- -
0.01
0.07
- -
0.16
Basic EPS, GAAP
-34.35
-28.45
-41.3
-145.65
-117.95
-75.12
-38.83
-66.59
-53.15
-59.81
- -
-5.28
Free Cash Flow per Basic Share
-30.88
-26.14
-38.17
-110.92
-106.4
-25.25
-68.36
-61.77
-54.21
-36.35
- -
-13.09
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.12
Book Value per Share
-85.32
-113.77
-155.07
-308.24
-321.51
-294.24
-274.17
-281.08
-283.66
-234.47
- -
-34.5
Tangible Book Value per Share
19.31
24.22
40.98
142.46
65.45
58.15
62.2
40.97
13.41
-15.72
- -
2.54
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
7
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
2
14
- -
- -
- -
1
1
Operating Margin (%)
- -
- -
- -
- -
- -
-988.96
-93
- -
-670,885.82
-65,456.83
-2,333.42
-2,012.57
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
Net Income, GAAP
-4
-4
-5
-17
-21
-20
-13
-28
-27
-50
-45
-33
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-988.49
-91.27
- -
-719,859.94
-86,888.57
-5,570.61
-3,163.01
Working Capital
2
3
5
17
11
15
11
23
11
-13
5
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
9
10
1
8
7
Total Equity
2
3
5
17
12
15
20
17
9
-13
41
58
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
26.86
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1
2
LT Borrowings
8
8
7
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
9
11
Market Capitalization
37
14
23

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
9
7
9
Cash, Cash Equivalents & STI
8
6
7
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
3
4
Payables & Accruals
3
2
2
ST Debt
- -
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-36.29%
-137.78%
-413.54%
Free Cash Flow
64.41%
91.26%
186.38%
Net Income, GAAP
43.52%
30.98%
-9.04%
Sales/Revenue/Turnover
- -
- -
1,318.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-18.75
-16.65
-9.07
- -
-59.81
2025
-1.59
-2.5
0.97
- -
- -
2026
0.76
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Hyunsu Jung
Full Time Employees
13
Sector
Healthcare
Industry
Medical - Devices
Address
295 Madison Avenue New York NY United States of America 10017
IPO Date
Jul 2, 2025
Business
Hyperion DeFi, Inc. (Nasdaq: HYPD) operates as a pioneering publicly listed company focused on building a strategic treasury reserve of Hyperliquid's native token, HYPE, while advancing ophthalmic delivery technology; it provides simplified access to the Hyperliquid ecosystem through DeFi strategies including staking, liquid staking via iHYPE and HiHYPE tokens, the HAUS (HYPE Asset Use Service) platform for fee generation, co-branded validators, and on-chain yield opportunities such as lending and liquidity provisioning on the HyperEVM. The company offers the proprietary Optejet User Filled Device (UFD), a topical ophthalmic medication dispensing platform designed for chronic front-of-the-eye diseases, artificial tears, and lens rewetting products; it features precise microdosing of 7-10 microliters per spray, horizontal delivery without head tilting, enhanced tolerability, and 98% first-attempt success rate versus traditional eye drops. Founded in 2014 and headquartered in Laguna Hills, California, Hyperion DeFi, formerly Eyenovia, Inc., conducts operations primarily in the United States with license agreements for MicroPine, MicroLine, and Mydcombi products including partnerships with Bausch Health Ireland Limited for the U.S. and Canada, and Arctic Vision and Senju Pharmaceutical for Asia; it targets institutional and retail participants in decentralized finance alongside ophthalmic patients and providers. Recent developments include a $50 million private placement in June 2025 to fund HYPE acquisitions, amassing over 1.5 million HYPE tokens; the appointment of Hyunsu Jung as Chief Investment Officer in 2025; launch of the HAUS platform with inaugural transactions alongside Credo in September 2025 for reduced trading fees and Felix in October 2025 for market launch fees; first institutional deposit into Kinetiq's iHYPE liquid staking protocol and a co-branded validator; a name change to Hyperion DeFi, Inc. on July 1, 2025; Fourth Amendment to its loan agreement with Avenue Capital extending maturity to 2028 and reducing interest rates; record Q3 2025 net income of $6.6 million driven by HYPE strategies; and anticipated FDA registration of the Optejet UFD in September 2025.

Company News

APIChat
  • Hyperion DeFi, Inc. (HYPD) Q1 2026 Earnings Call Transcript

  • Hyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026

  • Hyperion DeFi Announces Closing of Public Offering of Common Stock

  • Hyperion DeFi Announces Pricing of Public Offering of Common Stock

  • Hyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  • Hyperion DeFi Schedules First Quarter Earnings Call for Thursday, May 14 at 8:00 a.m. ET

  • Hyperion DeFi Announces Participation in Upcoming Investor and Industry Conferences

  • Hyperion DeFi (NASDAQ:HYPD) versus Neuren Pharmaceuticals (OTCMKTS:NURPF) Critical Survey

  • Hyperion DeFi, Inc. (HYPD) Q4 2025 Earnings Call Transcript

  • Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

  • Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Consensus Recommendation of “Hold” from Analysts

  • Hyperion DeFi Announces Private Lending Pool Built by HyperLend

  • Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis

  • Faron Pharmaceuticals Oy (OTC:FPHAF) & Hyperion DeFi (NASDAQ:HYPD) Financial Contrast

  • Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Average Rating of “Hold” from Analysts

  • Hyperion DeFi (NASDAQ:HYPD) CFO David Knox Acquires 27,950 Shares of Stock

  • Hyperion DeFi, Inc. (HYPD) Q3 2025 Earnings Call Transcript

  • Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

  • Many crypto-treasury companies are trading for less than what their digital assets are worth. Is this a bargain or a big red flag?

  • Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings